Low Migraine Recurrence With Intranasal DHE – MedPage Today

Read article - Stewart Tepper, professor of neurology, is quoted about research presented at the American Headache Society virtual meeting on the use of Intranasal INP104, dihydroergotamine mesylate (DHE) as a treatment for migraines. “One of the most useful features of DHE is that it tends to give a complete acute migraine treatment, that is, a pain-free response without return of headache and without need for retreatment or rescue medication -- a one-and-done outcome,” said Tepper.